Global Coronavirus Disease 2019 (COVID-19) Clinical Trials Research Report 2021 with Q4,2021 Database of Clinical Trials
Dublin, June 25, 2021 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Clinical Trials - Overview, Landscape, Trial using Vaccines vs. Therapeutics, and Trials Impacted by COVID-19" report has been added to ResearchAndMarkets.com's offering.
The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.
Scope
The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database.
The data included clinical trials that were captured in the database as of April 22, 2021.
The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and non-COVID-19 trials impacted due to the pandemic. Further analysis was conducted based on multinational vs. single country, clinical trial sites, status, primary endpoint status, terminated trials, phase, sponsor type, and upcoming milestone events.
Reasons to Buy
Understand the global COVID-19 landscape
The trends of vaccine COVID-19 clinical trials
The trends of therapeutic COVID-19 clinical trials
A closer look at the impact of the pandemic on non-COVID-19 trials
Key Topics Covered:
Executive Summary
Introduction
Analysis of COVID-19 Clinical Trials
COVID-19 Clinical Trials for Vaccines
COVID-19 Clinical Trials for Therapeutics
Impact of COVID-19 on Clinical Trials
Key Findings
Appendix
Key Tables
Top Countries with COVID-19 Key Stats
Key Figures
Impact of COVID-19
Top Countries in COVID-19 Key Stats
Landscape of Pipeline Candidates for COVID-19, by Phase
Landscape of Vaccines Candidates for COVID-19, by Phase
Number of COVID-19 Clinical Trials by Start Date, by Month
Number of COVID-19 Clinical Trials, by Multinational vs. Single Country
Single Country COVID-19 Clinical Trials, By Region & Phase
Multinational Country COVID-19 Clinical Trials, By Region & Phase
COVID-19 Clinical Trial Sites, by Region
COVID-19 Clinical Trial Sites, by Country & State
Number of COVID-19 Clinical Trials, by Phase & Status
Endpoint Status for Completed COVID-19 Clinical Trials
Top Reasons for Terminated Trials, by Phase
Top Reason for Terminated Trials, by Sponsor Type
COVID-19 Clinical Trials by Vaccine, by Month
Vaccine COVID-19 Clinical Trials, by Phase & Status
Vaccine COVID-19 Clinical Trials, by Sponsor Type
Top Industry Sponsors for COVID-19 Vaccine Clinical Trials
Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials
Pfizer/BioNTech's Tozinameran (Comirnaty), by Status & Phase
Moderna's mRNA-1273, by Status & Phase
Johnson & Johnson's JNJ-78436735, by Status & Phase
AstraZeneca's Covishield (Vaxzevria), by Status & Phase
Bharat Biotech's Covaxin, by Status & Phase
CanSino Biologics' Convidecia, by Status & Phase
SinoVac Biotech's CoronaVac, by Status & Phase
Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines
Clinical Trial Start Date to First Approval for Vaccines
COVID-19 Therapeutic Clinical Trials, by Month
Therapeutic COVID-19 Clinical Trials, by Phase & Status
Therapeutic COVID-19 Clinical Trials, by Sponsor Type
Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials
Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials
Gilead Sciences' Remdesivir (Veklury), by Status & Phase
Fujifim Toyama Chemical's Favipiravir, by Status & Phase
Eli Lilly's Bamlanivimab, by Status & Phase
Regeneron's Casirivimab + Imdevimab, by Status & Phase
Eli Lilly's Baricitinib, by Status & Phase
CytoDyn's Leronlimab, by Status & Phase
Upcoming Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs
Clinical Trials Disrupted Due to COVID-19
Disrupted Clinical Trials, by Reason
Disrupted Clinical Trials, by Therapy Area
Disrupted Clinical Trials Activities
Disrupted Clinical Trials, by Top Sponsors
Resumed Clinical Trials, by Top Five Therapy Areas
For more information about this report visit https://www.researchandmarkets.com/r/z8dexd
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900